Biodegradable core-multishell nanocarrier: Topical tacrolimus delivery for treatment of dermatitis

Two challenges in topical drug delivery to the skin include solubilizing hydrophobic drugs in water-based formulations and increasing drug penetration into the skin. Polymeric core-multishell nanocarrier (CMS), particularly the novel biodegradable CMS (bCMS = hPG-PCL1.1K-mPEG2k-CMS) have shown both...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2022-09, Vol.349, p.917-928
Hauptverfasser: Radbruch, Moritz, Pischon, Hannah, Du, Fang, Haag, Rainer, Schumacher, Fabian, Kleuser, Burkhard, Mundhenk, Lars, Gruber, Achim D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 928
container_issue
container_start_page 917
container_title Journal of controlled release
container_volume 349
creator Radbruch, Moritz
Pischon, Hannah
Du, Fang
Haag, Rainer
Schumacher, Fabian
Kleuser, Burkhard
Mundhenk, Lars
Gruber, Achim D.
description Two challenges in topical drug delivery to the skin include solubilizing hydrophobic drugs in water-based formulations and increasing drug penetration into the skin. Polymeric core-multishell nanocarrier (CMS), particularly the novel biodegradable CMS (bCMS = hPG-PCL1.1K-mPEG2k-CMS) have shown both advantages on excised skin ex vivo. Here, we investigated topical delivery of tacrolimus (TAC; > 500 g/mol) by bCMS in a hydrogel on an oxazolone-induced model of dermatitis in vivo. As expected, bCMS successfully delivered TAC into the skin. However, in vivo they did not increase, but decrease TAC penetration through the stratum corneum compared to ointment. Differences in the resulting mean concentrations were mostly non-significant in the skin (epidermis: 35.7 ± 20.9 ng/cm2 for bCMS vs. 92.6 ± 62.7 ng/cm2 for ointment; dermis: 76.8 ± 26.8 ng/cm2vs 118.2 ± 50.4 ng/cm2), but highly significant in blood (plasma: 1.1 ± 0.4 ng/ml vs 11.3 ± 9.3 ng/ml; erythrocytes: 0.5 ± 0.2 ng/ml vs 3.4 ± 2.4 ng/ml) and liver (0.01 ± 0.01 ng/mg vs 0.03 ± 0.01 ng/mg). bCMS were detected in the stratum corneum but not in viable skin or beyond. The therapeutic efficacy of TAC delivered by bCMS was equivalent to that of standard TAC ointment. Our results suggest that bCMS may be a promising carrier for the topical delivery of TAC. The quantitative difference to previous results should be interpreted in light of structural differences between murine and human skin, but highlights the need as well as potential methods to develop more a complex ex vivo analysis on human skin to ensure quantitative predictive value. [Display omitted] •Biodegradable core-multishell nanocarrier (bCMS) are a novel universal drug carrier.•bCMS topically deliver Tacrolimus (TAC) to the skin in a water-based formulation.•TAC delivered by bCMS effectively reduces inflammation in a dermatitis model.•In contrast to ex vivo results however, bCMS do not enhance TAC penetration in vivo.•Investigating differences between models will yield improved ex vivo predictions.
doi_str_mv 10.1016/j.jconrel.2022.07.025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2696860964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365922004448</els_id><sourcerecordid>2696860964</sourcerecordid><originalsourceid>FETCH-LOGICAL-c272t-76031c16c2e15de659c28f0dbe755e818b90d6c9c36c03f70f297c9da32866be3</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMoOI4-gtClm9YknSaNG1HxBoIbXYf05FQzpM2YZATf3gzj3tVZ_BfO_xFyzmjDKBOX62YNYY7oG045b6hsKO8OyIL1sq1XSnWHZFF8fd2KTh2Tk5TWlNKuXckFGW5dsPgRjTWDxwpCxHra-uzSJ3pfzWYOYGJ0GK-qt7BxYHyVDcTg3bRNlUXvvjH-VGOIVY5o8oRzrsJYlDiZ7ErRKTkajU949neX5P3h_u3uqX55fXy-u3mpgUueayloy4AJ4Mg6i-VV4P1I7YCy67Bn_aCoFaCgFUDbUdKRKwnKmpb3QgzYLsnFvncTw9cWU9aTS1BWmBnDNmkulOgFVWJVrN3eWoakFHHUm-gmE380o3rHVK_1H1O9Y6qp1IVpyV3vc1h2fBcoOoHDGdC6iJC1De6fhl86pITM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2696860964</pqid></control><display><type>article</type><title>Biodegradable core-multishell nanocarrier: Topical tacrolimus delivery for treatment of dermatitis</title><source>Access via ScienceDirect (Elsevier)</source><creator>Radbruch, Moritz ; Pischon, Hannah ; Du, Fang ; Haag, Rainer ; Schumacher, Fabian ; Kleuser, Burkhard ; Mundhenk, Lars ; Gruber, Achim D.</creator><creatorcontrib>Radbruch, Moritz ; Pischon, Hannah ; Du, Fang ; Haag, Rainer ; Schumacher, Fabian ; Kleuser, Burkhard ; Mundhenk, Lars ; Gruber, Achim D.</creatorcontrib><description>Two challenges in topical drug delivery to the skin include solubilizing hydrophobic drugs in water-based formulations and increasing drug penetration into the skin. Polymeric core-multishell nanocarrier (CMS), particularly the novel biodegradable CMS (bCMS = hPG-PCL1.1K-mPEG2k-CMS) have shown both advantages on excised skin ex vivo. Here, we investigated topical delivery of tacrolimus (TAC; &gt; 500 g/mol) by bCMS in a hydrogel on an oxazolone-induced model of dermatitis in vivo. As expected, bCMS successfully delivered TAC into the skin. However, in vivo they did not increase, but decrease TAC penetration through the stratum corneum compared to ointment. Differences in the resulting mean concentrations were mostly non-significant in the skin (epidermis: 35.7 ± 20.9 ng/cm2 for bCMS vs. 92.6 ± 62.7 ng/cm2 for ointment; dermis: 76.8 ± 26.8 ng/cm2vs 118.2 ± 50.4 ng/cm2), but highly significant in blood (plasma: 1.1 ± 0.4 ng/ml vs 11.3 ± 9.3 ng/ml; erythrocytes: 0.5 ± 0.2 ng/ml vs 3.4 ± 2.4 ng/ml) and liver (0.01 ± 0.01 ng/mg vs 0.03 ± 0.01 ng/mg). bCMS were detected in the stratum corneum but not in viable skin or beyond. The therapeutic efficacy of TAC delivered by bCMS was equivalent to that of standard TAC ointment. Our results suggest that bCMS may be a promising carrier for the topical delivery of TAC. The quantitative difference to previous results should be interpreted in light of structural differences between murine and human skin, but highlights the need as well as potential methods to develop more a complex ex vivo analysis on human skin to ensure quantitative predictive value. [Display omitted] •Biodegradable core-multishell nanocarrier (bCMS) are a novel universal drug carrier.•bCMS topically deliver Tacrolimus (TAC) to the skin in a water-based formulation.•TAC delivered by bCMS effectively reduces inflammation in a dermatitis model.•In contrast to ex vivo results however, bCMS do not enhance TAC penetration in vivo.•Investigating differences between models will yield improved ex vivo predictions.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2022.07.025</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Core-multishell (CMS) nanocarriers ; Dermal drug administration ; Drug delivery systems ; Penetration enhancement ; Tacrolimus ; Topical drug delivery</subject><ispartof>Journal of controlled release, 2022-09, Vol.349, p.917-928</ispartof><rights>2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c272t-76031c16c2e15de659c28f0dbe755e818b90d6c9c36c03f70f297c9da32866be3</citedby><cites>FETCH-LOGICAL-c272t-76031c16c2e15de659c28f0dbe755e818b90d6c9c36c03f70f297c9da32866be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2022.07.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997</link.rule.ids></links><search><creatorcontrib>Radbruch, Moritz</creatorcontrib><creatorcontrib>Pischon, Hannah</creatorcontrib><creatorcontrib>Du, Fang</creatorcontrib><creatorcontrib>Haag, Rainer</creatorcontrib><creatorcontrib>Schumacher, Fabian</creatorcontrib><creatorcontrib>Kleuser, Burkhard</creatorcontrib><creatorcontrib>Mundhenk, Lars</creatorcontrib><creatorcontrib>Gruber, Achim D.</creatorcontrib><title>Biodegradable core-multishell nanocarrier: Topical tacrolimus delivery for treatment of dermatitis</title><title>Journal of controlled release</title><description>Two challenges in topical drug delivery to the skin include solubilizing hydrophobic drugs in water-based formulations and increasing drug penetration into the skin. Polymeric core-multishell nanocarrier (CMS), particularly the novel biodegradable CMS (bCMS = hPG-PCL1.1K-mPEG2k-CMS) have shown both advantages on excised skin ex vivo. Here, we investigated topical delivery of tacrolimus (TAC; &gt; 500 g/mol) by bCMS in a hydrogel on an oxazolone-induced model of dermatitis in vivo. As expected, bCMS successfully delivered TAC into the skin. However, in vivo they did not increase, but decrease TAC penetration through the stratum corneum compared to ointment. Differences in the resulting mean concentrations were mostly non-significant in the skin (epidermis: 35.7 ± 20.9 ng/cm2 for bCMS vs. 92.6 ± 62.7 ng/cm2 for ointment; dermis: 76.8 ± 26.8 ng/cm2vs 118.2 ± 50.4 ng/cm2), but highly significant in blood (plasma: 1.1 ± 0.4 ng/ml vs 11.3 ± 9.3 ng/ml; erythrocytes: 0.5 ± 0.2 ng/ml vs 3.4 ± 2.4 ng/ml) and liver (0.01 ± 0.01 ng/mg vs 0.03 ± 0.01 ng/mg). bCMS were detected in the stratum corneum but not in viable skin or beyond. The therapeutic efficacy of TAC delivered by bCMS was equivalent to that of standard TAC ointment. Our results suggest that bCMS may be a promising carrier for the topical delivery of TAC. The quantitative difference to previous results should be interpreted in light of structural differences between murine and human skin, but highlights the need as well as potential methods to develop more a complex ex vivo analysis on human skin to ensure quantitative predictive value. [Display omitted] •Biodegradable core-multishell nanocarrier (bCMS) are a novel universal drug carrier.•bCMS topically deliver Tacrolimus (TAC) to the skin in a water-based formulation.•TAC delivered by bCMS effectively reduces inflammation in a dermatitis model.•In contrast to ex vivo results however, bCMS do not enhance TAC penetration in vivo.•Investigating differences between models will yield improved ex vivo predictions.</description><subject>Core-multishell (CMS) nanocarriers</subject><subject>Dermal drug administration</subject><subject>Drug delivery systems</subject><subject>Penetration enhancement</subject><subject>Tacrolimus</subject><subject>Topical drug delivery</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKxDAUhoMoOI4-gtClm9YknSaNG1HxBoIbXYf05FQzpM2YZATf3gzj3tVZ_BfO_xFyzmjDKBOX62YNYY7oG045b6hsKO8OyIL1sq1XSnWHZFF8fd2KTh2Tk5TWlNKuXckFGW5dsPgRjTWDxwpCxHra-uzSJ3pfzWYOYGJ0GK-qt7BxYHyVDcTg3bRNlUXvvjH-VGOIVY5o8oRzrsJYlDiZ7ErRKTkajU949neX5P3h_u3uqX55fXy-u3mpgUueayloy4AJ4Mg6i-VV4P1I7YCy67Bn_aCoFaCgFUDbUdKRKwnKmpb3QgzYLsnFvncTw9cWU9aTS1BWmBnDNmkulOgFVWJVrN3eWoakFHHUm-gmE380o3rHVK_1H1O9Y6qp1IVpyV3vc1h2fBcoOoHDGdC6iJC1De6fhl86pITM</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Radbruch, Moritz</creator><creator>Pischon, Hannah</creator><creator>Du, Fang</creator><creator>Haag, Rainer</creator><creator>Schumacher, Fabian</creator><creator>Kleuser, Burkhard</creator><creator>Mundhenk, Lars</creator><creator>Gruber, Achim D.</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202209</creationdate><title>Biodegradable core-multishell nanocarrier: Topical tacrolimus delivery for treatment of dermatitis</title><author>Radbruch, Moritz ; Pischon, Hannah ; Du, Fang ; Haag, Rainer ; Schumacher, Fabian ; Kleuser, Burkhard ; Mundhenk, Lars ; Gruber, Achim D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c272t-76031c16c2e15de659c28f0dbe755e818b90d6c9c36c03f70f297c9da32866be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Core-multishell (CMS) nanocarriers</topic><topic>Dermal drug administration</topic><topic>Drug delivery systems</topic><topic>Penetration enhancement</topic><topic>Tacrolimus</topic><topic>Topical drug delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Radbruch, Moritz</creatorcontrib><creatorcontrib>Pischon, Hannah</creatorcontrib><creatorcontrib>Du, Fang</creatorcontrib><creatorcontrib>Haag, Rainer</creatorcontrib><creatorcontrib>Schumacher, Fabian</creatorcontrib><creatorcontrib>Kleuser, Burkhard</creatorcontrib><creatorcontrib>Mundhenk, Lars</creatorcontrib><creatorcontrib>Gruber, Achim D.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Radbruch, Moritz</au><au>Pischon, Hannah</au><au>Du, Fang</au><au>Haag, Rainer</au><au>Schumacher, Fabian</au><au>Kleuser, Burkhard</au><au>Mundhenk, Lars</au><au>Gruber, Achim D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biodegradable core-multishell nanocarrier: Topical tacrolimus delivery for treatment of dermatitis</atitle><jtitle>Journal of controlled release</jtitle><date>2022-09</date><risdate>2022</risdate><volume>349</volume><spage>917</spage><epage>928</epage><pages>917-928</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Two challenges in topical drug delivery to the skin include solubilizing hydrophobic drugs in water-based formulations and increasing drug penetration into the skin. Polymeric core-multishell nanocarrier (CMS), particularly the novel biodegradable CMS (bCMS = hPG-PCL1.1K-mPEG2k-CMS) have shown both advantages on excised skin ex vivo. Here, we investigated topical delivery of tacrolimus (TAC; &gt; 500 g/mol) by bCMS in a hydrogel on an oxazolone-induced model of dermatitis in vivo. As expected, bCMS successfully delivered TAC into the skin. However, in vivo they did not increase, but decrease TAC penetration through the stratum corneum compared to ointment. Differences in the resulting mean concentrations were mostly non-significant in the skin (epidermis: 35.7 ± 20.9 ng/cm2 for bCMS vs. 92.6 ± 62.7 ng/cm2 for ointment; dermis: 76.8 ± 26.8 ng/cm2vs 118.2 ± 50.4 ng/cm2), but highly significant in blood (plasma: 1.1 ± 0.4 ng/ml vs 11.3 ± 9.3 ng/ml; erythrocytes: 0.5 ± 0.2 ng/ml vs 3.4 ± 2.4 ng/ml) and liver (0.01 ± 0.01 ng/mg vs 0.03 ± 0.01 ng/mg). bCMS were detected in the stratum corneum but not in viable skin or beyond. The therapeutic efficacy of TAC delivered by bCMS was equivalent to that of standard TAC ointment. Our results suggest that bCMS may be a promising carrier for the topical delivery of TAC. The quantitative difference to previous results should be interpreted in light of structural differences between murine and human skin, but highlights the need as well as potential methods to develop more a complex ex vivo analysis on human skin to ensure quantitative predictive value. [Display omitted] •Biodegradable core-multishell nanocarrier (bCMS) are a novel universal drug carrier.•bCMS topically deliver Tacrolimus (TAC) to the skin in a water-based formulation.•TAC delivered by bCMS effectively reduces inflammation in a dermatitis model.•In contrast to ex vivo results however, bCMS do not enhance TAC penetration in vivo.•Investigating differences between models will yield improved ex vivo predictions.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.jconrel.2022.07.025</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2022-09, Vol.349, p.917-928
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_2696860964
source Access via ScienceDirect (Elsevier)
subjects Core-multishell (CMS) nanocarriers
Dermal drug administration
Drug delivery systems
Penetration enhancement
Tacrolimus
Topical drug delivery
title Biodegradable core-multishell nanocarrier: Topical tacrolimus delivery for treatment of dermatitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T15%3A56%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biodegradable%20core-multishell%20nanocarrier:%20Topical%20tacrolimus%20delivery%20for%20treatment%20of%20dermatitis&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Radbruch,%20Moritz&rft.date=2022-09&rft.volume=349&rft.spage=917&rft.epage=928&rft.pages=917-928&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2022.07.025&rft_dat=%3Cproquest_cross%3E2696860964%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2696860964&rft_id=info:pmid/&rft_els_id=S0168365922004448&rfr_iscdi=true